tofacitinib citrate topical gel (AC-1101) / Bora Pharma, ImageneBio - LARVOL DELTA

Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare (clinicaltrials.gov) - P1 | N=13 | Completed | Sponsor: TWi Biotechnology, Inc. | Recruiting ➔ Completed

Trial completion • Rare Diseases

Tofacitinib Citrate-loaded Nanoparticle Gel for the Treatment of Alopecia Areata: Response Surface Design, Formulation and In vitro-in Vivo Characterization. (PubMed, Recent Adv Drug Deliv Formul) - "Based on the results, the NPs and NPG formulations were depicted to enhance the activity of TFN compared to the free drug solution. TFN could be a safe and effective treatment for Alopecia areata. The tofacitinib citrate NPG could be a clinically translatable, safer topical formulation for managing Alopecia areata."

Journal • Preclinical • Addiction (Opioid and Alcohol) • Alopecia • Immunology

TWi Biotechnology Exploring Promising Treatment for Granuloma Annulare (GA) (BioSpace) - "TWi Biotechnology...is currently seeking participants for a Phase 1 clinical trial of a topical gel called tofacitinib for the treatment of granuloma annulare (GA). The TWiB team and collaborating physicians invite eligible individuals to participate in this groundbreaking study at Yale University Hospital."

Trial status • Immunology

[Announcement] Ancheng Biotechnology's new drug AC-1101 for the treatment of atopic dermatitis (Atopic Dermatitis) has been approved by the US Food and Drug Administration (US FDA) to conduct the first phase of human clinical trials. [Google translation] (stock.yahoo) - "Ancheng Biotech's new drug AC-1101 for the treatment of atopic dermatitis has been approved by the US Food and Drug Administration (US FDA) for the first phase of human clinical trials."

IND • New P1 trial • Atopic Dermatitis • Dermatology • Immunology

Design of chondroitin sulphate coated proglycosomes for localized delivery of tofacitinib for the treatment of rheumatoid arthritis. (PubMed, Eur J Pharm Biopharm) - "The efficacy study revealed that CS-TOF-PG showed a significant (P < 0.001) reduction in inflammation in arthritic rat paws compared to the TOF oral and FD gel. The current study ensured that the CS-TOF-PG topical gel system would provide a safe and effective formulation for localization and site-specific delivery of TOF at the RA site and overcome the adverse effects associated with the TOF."

Journal • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients With Granuloma Annulare (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: TWi Biotechnology, Inc. | Trial completion date: May 2023 ➔ Oct 2023 | Trial primary completion date: May 2023 ➔ Oct 2023

Trial completion date • Trial primary completion date • Rare Diseases

Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients With Granuloma Annulare (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: TWi Biotechnology, Inc.

New P1 trial • Rare Diseases